UCB Acquires Element Genomics

UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina. The total cost of the transaction, including upfront and short-term success-based milestone payments, will amount to up to USD 30 million.

At the core of the Element Genomics platform is a suite of technologies to improve understanding of genome structure and function such as CRISPR editing technologies used for genomic and epigenomic regulatory region analysis and modulation, underpinned and enabled with advanced informatics capabilities, and driven by a strong scientific team. Element Genomics' technologies and expertise will enhance UCB's scientific research platform enabling the company to continue to enrich its pipeline, in particular strengthening target discovery and characterization in disease relevant systems.

"Element Genomics researchers have a stellar reputation and their scientific expertise in genomics and epigenomics will complement UCB's, allowing us to deepen our understanding of disease mechanisms with the aim of developing targeted therapies. We look forward to working with the Element Genomics team and welcome them within UCB," Dhavalkumar Patel, UCB's Chief Scientific Officer said.

Element Genomics' team will continue to be based in downtown Durham, North Carolina, and will work very closely with UCB's international research teams. Close cooperation will be pursued with Duke University and the Element Genomics founders, Duke University Professors Charles Gersbach, Greg Crawford, Tim Reddy and Kris Wood.

Register as Visitor to CPhI China 2018!